Facility Needs Panel Recommends $4.5-3 billion, Seven Year Program To Be Run By NIGMS Or DRR
In Brief: MB Ends Apportionment Carlo Croce To Head Fels Institute, Replacing Peter Magee Sept. 1
DCT To Renegotiate Cooperative Groups Term Of Award, Considering Other Major Changes
William Tipping New ACS Executive VP; Murphy To Replace Holleb, Laszio Takes Rauscher’s Position
CCOP Review Committee Member Objects To “Unwarranted Criticism”
CTEP Drafts FDA Approval Guidelines
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- What happened at FDA? Replimune approval raises questions
- I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial









